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http://dx.doi.org/10.1016/j.ccr.2012.07.014SUMMARYDiffuse large B cell lymphoma (DLBCL) is a clinically and biologically heterogeneous disease with a high
proliferation rate. By integrating copy number datawith transcriptional profiles and performing pathway anal-
ysis in primary DLBCLs, we identified a comprehensive set of copy number alterations (CNAs) that decreased
p53 activity and perturbed cell cycle regulation. Primary tumors either had multiple complementary alter-
ations of p53 and cell cycle components or largely lacked these lesions. DLBCLs with p53 and cell cycle
pathway CNAs had decreased abundance of p53 target transcripts and increased expression of E2F target
genes and the Ki67 proliferation marker. CNAs of the CDKN2A-TP53-RB-E2F axis provide a structural basis
for increased proliferation in DLBCL, predict outcome with current therapy, and suggest targeted treatment
approaches.INTRODUCTION
Diffuse large B cell lymphoma (DLBCL) is themost common non-
Hodgkin lymphoma in adults and a clinically and genetically
heterogeneous disorder. With current immunochemotherapy,
over 60% of patients with DLBCL can be cured; however, the re-
maining patients succumb to their disease (Friedberg and Fisher,
2008). Despite recent advances in the molecular understandingSignificance
In spite of advances in the molecular understanding of DLBCL
risk patients who then receive empiric therapy. In DLBCLs, wh
and RB1, the current studies define an alternative copy numbe
This genetic signature predicts outcome and suggests target
kinase inhibition.
Canof DLBCL pathogenesis, clinical risk factor models are still
used to identify patients who are unlikely to be cured with current
therapy. The most widely used model is the International Prog-
nostic Index (IPI), an outcome predictor based on easily measur-
able clinical parameters including age, performance status,
serum lactate dehydrogenase (LDH), Ann Arbor stage, and
number of extranodal disease sites (Shipp et al., 1993). Although
the IPI is robust and reproducible, the link between the includedpathogenesis, clinical models are still used to identify high-
ich have infrequent inactivating somatic mutations of TP53
r-dependent mechanism of deregulating p53 and cell cycle.
ed approaches to treatment such as pan cyclin-dependent
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remains to be defined.
In previous studies, increased cellular proliferation has also
been associated with unfavorable outcome in DLBCL. Indirect
indices of cellular proliferation included elevated serum LDH as
a component of the IPI and increased expression of the Ki67
nuclear antigen (Grogan et al., 1988; Salles et al., 2011).
DLBCLs largely originate from germinal center (GC) B cells,
which have high growth rates and increased genomic instability
(Klein and Dalla-Favera, 2008). GC B cells undergo somatic
hypermutation (SHM) of their immunoglobulin variable region
genes and class-switch recombination (CSR) to alter their immu-
noglobulin subtype. The rapid proliferation rate and errors in CSR
and SHM predispose normal GC B cells to malignant transfor-
mation. As a consequence, DLBCLs exhibit multiple low fre-
quency genetic alterations including chromosomal transloca-
tions, somatic mutations, and copy number alterations (CNAs).
Given the numbers and types of genetic alterations in DLBCL,
investigators have sought additional comprehensive classifica-
tion systems to identify groups of tumors with similar molecular
traits. Transcriptional profiling has been used to define DLBCL
subsets that share certain features with normal B cell subtypes
(‘‘cell-of-origin’’ [COO] classification) (Lenz and Staudt, 2010).
COO-defined DLBCLs include ‘‘germinal center B cell’’ (GCB)
and ‘‘activated B cell’’ (ABC) types and an additional group of
unclassified tumors. The COO-defined tumor groups are charac-
terized by certain biological features, most notably increased
NFkB activity and less favorable outcome in ABC-type DLBCLs
(Lenz and Staudt, 2010). However, the outcome differences in
GCB and ABC-type DLBCLs may be less striking in patients
treated with current rituxan-containing combination chemo-
therapy regimens (Fu et al., 2008; Lenz et al., 2008a). An alterna-
tive transcriptional profiling classification, termed comprehen-
sive consensus clustering, identifies DLBCL subtypes solely on
the basis of distinctions within primary tumors and includes
the three groups: ‘‘B cell receptor,’’ ‘‘oxidative phosphorylation,’’
and ‘‘host-response’’ (Chen et al., 2008; Monti et al., 2005).
To date, genetic alterations in DLBCL have largely been ana-
lyzedassingle featuresor inassociationwith thedefinedtranscrip-
tional subtypes (Bea et al., 2005; Lenz et al., 2008b). The platforms
that were previously used to define CNAs in DLBCL had lower
resolution, and concordant assessments of transcript abundance
and copy number (CN) were more limited. For these reasons, the
precise boundaries of CNAs, the associated candidate ‘‘driver
genes,’’ and implicated pathways require further definition.
The earlier observations regarding cellular proliferation in
DLBCL prompted additional analyses of certain individual cell
cycle components and regulators. Cell cycle progression is
controlled by series of cyclin-dependent kinases (CDKs), which
are complexed with specific cyclins (Malumbres and Barbacid,
2009). The cyclin D-dependent kinases 4 and 6 (CDK4/CDK6)
and the cyclin E-associated kinase 2 (CDK2) sequentially phos-
phorylate the retinoblastoma (RB) proteins, releasing the E2F
transcription factors and promoting cell cycle progression. The
A-type cyclins also activate CDK2 and CDK1 promoting S phase
transition and the onset of mitosis. CDK activity is regulated
by inhibitors, such as the INK4 family member p16INK4A (at the
CDKN2A locus), and certain p53 targets, such as p21, among
others (Malumbres and Barbacid, 2009). Individual cell cycle360 Cancer Cell 22, 359–372, September 11, 2012 ª2012 Elsevier Incomponents and regulators reported to be perturbed in small
numbers of DLBCLs include CDKN2A (ARF and p16INK4A), p53
and its target p21, cyclin D3, and RB1 (Jardin et al., 2010; Pas-
qualucci et al., 2011; Sa´nchez-Beato et al., 2003; Winter et al.,
2010; Young et al., 2008). Recent deep sequencing analyses
confirm earlier reports of TP53 somatic mutations in approxi-
mately 20% of DLBCLs (Morin et al., 2011; Pasqualucci et al.,
2011; Lohr et al., 2012), a much lower percentage than in certain
nonhematologic malignancies (Cancer Genome Atlas Research
Network, 2008, 2011). The relatively low frequency of TP53
somatic alterations in primary human DLBCLs suggests that
additional bases of p53 deficiency remain to be defined.
Herein, we integrate CN data with transcriptional profiles and
perform pathway analyses to identify core deregulated and tar-
getable pathways in primary DLBCLs.
RESULTS
Mapping Recurrent CNAs in Primary DLBCL
Recurrent CNAs in the 180 primary DLBCLs were detected
using the Genomic Identification of Significant Targets in Cancer
(GISTIC) algorithm.Within the identified regions of significant CN
gain or loss, narrower peaks of maximally significant CN change
were identified (Supplemental Experimental Procedures avail-
able online). We found 47 recurrent CNAs, including 21 copy
gains and 26 copy losses, with frequencies of 4% to 27% (Fig-
ure 1; Table S1). The GISTIC-defined CNAs range from narrow
focal alterations, such as amplification peak 2p16.1 to chromo-
some arm and whole-chromosome alterations, including gain
of 1q, loss of 6q, and gain of chromosome 7 (Figure 1).
Comparison of CNAs in DLBCLs and Nonhematologic
Cancers
TodistinguishbetweenCNAs that areunique toDLBCLand those
that are found in other tumors, we compared the DLBCL GISTIC
analysis to that of 2,433 nonhematologic cancers (Beroukhim
et al., 2010). The CNAs in DLBCLs and the nonhematologic
cancers were visualizedwith amirror plot (Figure 2), and the CNA
overlap in the two series was computed (Figure S1A; Supple-
mental Experimental Procedures). Seven of 21 (33%) regions of
copy gain and 16/26 (62%) regions of copy loss were common
to both series; additional regions of copy gain exhibited partial
overlap (Figures 2 and S1A). Examples of shared alterations
include gains of chromosome 7 and chromosome 1q and loss
of chromosome 6q, suggesting a broader role for these alter-
ations in multiple tumor types. In contrast, 9/21 (43%) regions
of copygain and10/26 (38%) regionsof copy losswere only iden-
tified inDLBCL, includinggainsof 2p16.1and19q13.42 (Figures2
and S1A). These DLBCL-selective CNAs were largely absent in
a lymphoid malignancy of non-GC origin (Figure S1B).
Integrative Analysis of CNAs and Transcript Abundance
We anticipated that DLBCL CNAs would alter the corresponding
gene transcript levels and prioritized genes with the most signif-
icant association between transcript abundance and CNA. All
genes within the 47 defined CNA peaks and regions (Table S2)
were analyzed for the association between transcript abundance
and the presence/absence of the gene alteration (peak or region)
across the DLBCL series. The ‘‘cis-signature’’ of a given CNAc.
Figure 1. Recurrent CNAs in Newly Diagnosed DLBCLs
GISTIC summary plots of the significant CN gains (left panel, red) and CN losses (right panel, blue) in 180 primary DLBCLs are displayed by chromosomal position
(y axis). FDR q values <.25 (right of the green line, x axis) are considered statistically significant. The chromosomal bands, GISTIC peak boundaries, frequencies of
alterations (n [%]), and top five genes by integrative analyses of CN and transcript abundance are listed below.
See also Tables S1, S2, and S3.
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Figure 2. Comparison of CNAs in Primary DLBCLs and Nonhematologic Cancers
The GISTIC-defined recurrent CNAs in the 180 primary DLBCLs (B) are compared to those in 2,433 nonhematologic cancers from a publicly available database
(A; Beroukhim et al., 2010) in a mirror plot with chromosome position on the y axis, significance (q value) on the x axis, CN gain in red and CN loss in blue. Green
line denotes FDR values <.25.
See also Figure S1.
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with the most significant association between CN and transcript
abundance (false discovery rate [FDR] q values % .25; top five
peak transcripts; Figure 1; Table S1; complete list, Table S3).
CNAs of Genes with Known Roles in Lymphomagenesis
The two genes most closely associated with the 6q21 and
6q23.3 copy loss were PRDM1 (BLIMP1) and TNFAIP3 (A20),
respectively (Figure 1; Table S1). Both genes are confirmed
tumor suppressors that can be inactivated by several mecha-
nisms, including copy loss (Calado et al., 2010; Kato et al.,
2009; Pasqualucci et al., 2006). Deletion of the ubiquitin-editing
enzyme, TNFAIP3, contributes to lymphoid transformation, in
part, by deregulating NFkB signaling (Shembade et al., 2010).
Inactivation of the PRDM1 transcriptional repressor promotes
lymphomagenesis by blocking normal plasma cell differentiation
(Mandelbaum et al., 2010).
The additional tumor suppressor genes, CDKN2A, RB1,
FAS, and TP53 were closely associated with 9p21.3, 13q14.2,
10q23.31, and 17p13.1 copy loss, respectively (Figure 1), con-
sistent with earlier analyses (Jardin et al., 2010; Sa´nchez-Beato
et al., 2003). Furthermore, two well-known oncogenes were362 Cancer Cell 22, 359–372, September 11, 2012 ª2012 Elsevier Intightly linked with amplification peaks, REL at 2p16.1 and
BCL2 at 18q21.33 (Figure 1). Copy gains of 2p16.1/REL and
12q15 were more frequent in GCB DLBCLs whereas gains of
18q21.32/BCL2 and 19q13.42 were more common in ABC
tumors, as described (Table S1) (Bea et al., 2005; Lenz et al.,
2008b). Given the identification of known CNAs in DLBCL, the
integrative analysis will likely define additional CNAs and genes
with previously unappreciated roles in the disease.
CNAs of Newly Identified Genes in DLBCL
The genes most closely associated with amplification of 1q23.3
(seen in 15% of DLBCLs) encode the low-affinity receptors for
the IgG Fc receptors, FCGR2B (CD32B) and FCGR2C, and the
related protein, FCRLA (FCRL1) (Figure 1). Increased FCGR2B
expression was previously associated with adverse outcome in
DLBCL (Camilleri-Broe¨t et al., 2004), and FCGR2C CN varia-
tion and overexpression were linked with certain autoimmune
diseases (Breunis et al., 2008). In addition, FCRLA was preferen-
tially expressed in B cells and postulated to be an activating cor-
eceptor (Leu et al., 2005).
Genes associated with amplification of the 19q13.42 region
include protein arginine methyl tranferase 1 (PRMT1) andc.
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H4 at arginine 3, which generally serves as an activation signal
(Nicholson et al., 2009). In addition, PRMT1 modifies transcrip-
tion factors including FOXO1 (Yamagata et al., 2008) and
signaling intermediaries such as the Iga subunit of the B cell
receptor (Infantino et al., 2010). BCL2L12 is an atypical BCL2
family member with cytoplasmic and nuclear roles. Cytoplasmic
BCL2L12 inhibits caspases 3 and 7, whereas nuclear BCL2L12
interacts with p53 and inhibits its binding to target gene
promoters (Stegh and DePinho, 2011).
CNAs of Genes Required for Tumor ImmuneRecognition
In addition to identifying individual genes targeted by specific
CNAs, we noted several alterations that perturbed genes
required for tumor immune recognition. Copy loss of 6q21.33
decreased the abundance of the major histocompatibility com-
plex (MHC) class I molecules, HLA-B and HLA-C, at the peak,
and the MHC class I polypeptide-related sequences A and B,
MICA and MICB, in the region (Figure 1; Table S1). In addition,
copy loss of 15q21.1 and 1p13.1 reduced the abundance of
the peak b2 microglobulin (b2M) and CD58 transcripts, respec-
tively (Figure 1), and 19p13.3 copy loss decreased the levels of
the region TNFSF9 (CD137L) transcripts (Table S1).
The b2M polypeptide associates with histocompatibility
complex antigen (HLA) class I heavy chains on the cell surface
to present antigen. In the absence of b2M, stable antigen-HLA
class I complexes cannot be formed. Both HLA class I and
B2M copy loss were previously described in large B cell
lymphomas of immunoprivileged sites (Booman et al., 2008; Jor-
danova et al., 2003), and inactivating mutations and deletions of
B2M were recently reported in DLBCLs (Challa-Malladi et al.,
2011; Pasqualucci et al., 2011).
The 6q21.33 region genes, MICA and MICB (Table S1),
encode ligands of the activating NKG2D receptor, which is
expressed by natural killer (NK) cells and a subset of T cells (Rau-
let, 2003). Decreased expression of these NKG2D ligands likely
limits an innate NK-cell mediated antitumor immune response.
The 1p13.1 peak gene, CD58 (LFA3) (Figure 1), encodes
a member of the immunoglobulin superfamily that is a ligand
for the costimulatory CD2 receptor on T and NK cells. CD58
was recently reported to be the target of inactivating somatic
mutations in a small subset of DLBCLs (Challa-Malladi et al.,
2011; Pasqualucci et al., 2011), providing additional evidence
that CD58 loss promotes tumor immune escape.
The 19p13.3 region gene, TNFSF9 (Table S1), encodes the
ligand for the CD137 costimulatory receptor, which is expressed
by follicular dendritic cells (FDC) and primed CD8+ memory
T cells (Middendorp et al., 2009). Interactions between TNFSF9
on GC B cells and CD137 on FDC and T cells regulate the GC
B cell response, and TNFSF9 loss promotes the development
of GCB lymphomas (Middendorp et al., 2009).
Pathway Enrichment Analyses Reveal Coordinate
Deregulation of p53 Signaling and Cell Cycle
After identifying CNAs of several genes required for tumor
immune recognition, we sought a more comprehensive method
to characterize additional pathways perturbed by CNAs in
DLBCL. We first defined global cis-acting peak or region signa-
tures as the union of all individual cis-acting peak or region
signatures (Figure 3Aa). Thereafter, we performed pathwayCanenrichment of the global signatures using a curated series of
gene sets and ranked the results by FDR (Figures 3Aa and 3B,
top pathways; Table S4, full analysis). In the global peak signa-
ture, 13 of 15 of the most significantly enriched gene sets reflect
related aspects of p53 signaling, apoptosis, and cell cycle regu-
lation (Figure 3B, top panel; FDR < .10). Although the gene sets
have different names, they include common genes that are tar-
geted by CNAs—TP53, CDKN2A, RB1, and RBL2 (all copy
loss) and BCL2 (copy gain) (Figure 3B, top panel).
In the global region signature, the most significantly enriched
gene set is the ‘‘p53 signaling pathway’’ (Figure 3B, bottom
panel, FDR .0003). Additional p53 pathway components altered
by CNAs include the p53 modifiers,MDM2,MDM4, and RFWD2
(COP1) (all copy gain); p53 targets, PERP, SCOTIN, TNFRSF10
(DR5/TRAIL receptor), and FAS (all copy loss); and critical cell
cycle regulators, CCND3 (cyclin D3), CDK4, CDK6, and CDK2
(all copy gain) (Figure 3B, bottom panel).
Components of the p53, Apoptotic, and Cell Cycle
Pathways Perturbed by CNAs
CNAs of p53, apoptotic, and cell cycle pathway members are
illustrated in Figure 4.
p53 Pathway
CNAs of p53 pathway components all had the same predicted
downstream effect—decreased abundance of functional p53
and reduced levels of associated p53 targets. Copy loss of
CDKN2A, at 9p21.3, occurs in 24% of DLBCLs (Figure 4). The
two alternative transcripts derived from the CDKN2A locus,
p16INK4A, and ARF have complementary roles in p53 signaling
and cell cycle regulation. ARF interferes with binding of the
MDM2E3 ligase to p53, decreasing its ubiquitylation and protea-
somal degradation (Brooks and Gu, 2006). As a consequence,
CDKNA2 deletion (ARF loss) and MDM2 (12q15) amplification
both increase the ubiquitylation and subsequent degradation
of p53 (Figure 4). Two additional E3 ligases with complementary
but largely nonoverlapping functions in destabilizing cellular p53
levels, MDM4 andRFWD2 (COP1), are increased by 1q23.3 copy
gain (Figure 4) (Dornan et al., 2004).
Moreover, TP53 itself and two positive p53 modifiers, RPL26
and KDM6B (JMJD3), are targeted by 17p13.1 copy loss (Fig-
ure 4). The H3K27 demethylase, KDM6B, participates in the
active removal of the repressive methyl mark from p16INK4A-
ARF, contributing to its transcriptional activation (Agger et al.,
2009). Therefore, KDM6B copy loss represents an additional
mechanism of indirectly reducing functional p53 activity (Fig-
ure 4). KDM6B also directly modulates p53 methylation, cellular
distribution, and function (Sola et al., 2011). The other positive
modifier of p53 activity, RPL26, binds to the 50 untranslated
region (UTR) of TP53, promotes its translation, and significantly
increases stress-induced p53 levels (Chen and Kastan, 2010;
Takagi et al., 2005) (Figure 4). RPL26 is also a target of MDM2,
which polyubiquitylates the ribosomal protein and enhances its
proteasomal degradation (Ofir-Rosenfeld et al., 2008) (Figure 4).
In addition, the recently identified negative modulator of p53
transcriptional activity, BCL2L12 (at 19q13.42), is amplified in
a subset of DLBCLs (Figure 4).
Apoptotic Pathways
Independent of its role in regulating p53, BCL2L12 amplification
limits apoptosis by blocking the effector caspases 3 and 7cer Cell 22, 359–372, September 11, 2012 ª2012 Elsevier Inc. 363
Figure 3. Pathway and TF Binding Site
Enrichment
(A) Schema for pathway and TF binding site
enrichment. (a) Pathway analysis. For eachGISTIC
peak and region, a ‘‘cis-acting gene signature’’
was defined, which included the genes within
a GISTIC alteration with a significant (FDR <.25)
correlation between CN and gene expression (left
panel). The global cis-acting signature, the union
of all individual cis-acting signatures, was ana-
lyzed for pathway enrichment using a pathway
compendium (C2, MSigDB). (b) TF binding site
analysis schema. The ‘‘trans-acting signature’’ of
each CNA (those genes outside the CNA with the
most significant association between transcript
abundance and the CNA) was defined (left panel),
and the union of the cis- and trans-acting signa-
tures was then tested for enrichment of genes with
common TF binding sites using a TF binding site
compendium (C3, MSigDB).
(B) Pathway analysis. The results of global cis-
acting signature pathway enrichment, separated
for peaks (upper panel) and regions (lower panel),
were ranked by FDR (FDR % .10, peaks; top set,
region; amplified genes in red, deleted genes in
blue). In the region pathway analysis, the set
annotation is ‘‘out of 1,893’’ instead of ‘‘out of
173’’(**).
(C) TF binding site analysis. The results were
ranked by FDR (FDR% .1 shown here).
See also Table S4.
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apoptotic pathway is BCL2 copy gain (18q21.33) (Figure 4).
Copy loss also decreases the abundance of several p53 targets
that promote apoptosis, including the extrinsic apoptotic
pathway components, FAS, TNFRF10B, SCOTIN, and PERP364 Cancer Cell 22, 359–372, September 11, 2012 ª2012 Elsevier Inc.(Figure 4) (Beaudry et al., 2010; Bourdon
et al., 2002; Wilson et al., 2009).
Cell Cycle Degregulation
The loss of p16INK4A and decreased
abundance of p53 targets, such as p21
and GADD45, relieve repression of the
cell cycle components, CCND3 (cyclin
D3), CDK2, and CDK1, respectively (Fig-
ure 4). In addition, CDK2, CCND3, and
the cyclin D-associated CDKs, CDK4,
and CDK6, are increased by copy gain
(Figure 4). In addition, RB1 and the
related RB locus, RBL2 (p130), are tar-
geted by copy loss in a subset of DLBCLs
(Figure 4). RB1 is also a recognized target
of theMDM2 E3 ligase (Polager andGins-
berg, 2009).
Signature of E2F Activation
We next sought an unbiased approach to
assess the relationship between CNA-
dependent changes and the abundance
of E2F target genes. Because transcrip-
tion factors (TF), such as E2F, will target
genes outside the identified CNAs, wefirst defined the ‘‘trans-acting signature’’ of each CNA (those
genes outside the CNA with the most significant association
between transcript abundance and the CNA; Figure 3Ab). The
union of the cis- and trans-acting signatures, termed the ‘‘global
cis/trans-acting transcriptional signature,’’ was then tested for
Figure 4. Components of the p53, Apoptotic, and Cell Cycle Pathways Perturbed by CNAs
Components include genes identified by the cis-signature pathway enrichment (Figure 3B) and three recently described p53 modifiers and cis-signature genes,
RPL26, KDM6B/JMJD3, and BCL2L12, that are not captured by the current annotated gene sets. Amplified genes, red; deleted genes, blue. For each CNA, the
locus, peak, or region gene and frequency of alteration are noted (right).
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The ‘‘global cis/trans-acting transcriptional signature’’ was sig-
nificantly enriched for genes containing E2F binding sites;
specifically, 7/7 of top-ranked binding sites were either E2F,
E2F/DP1, or E2F/DP2 (Figure 3C; full list in Table S4). Therefore,
DLBCL CNAs are tightly associated with cell cycle deregulation
and increased abundance of E2F target genes.
Patterns of CNAs of Pathway Components
The analysis of CNAs that perturb p53 signaling, apoptosis, and
cell cycle regulation also illustrates four important principles.
First, a single CNAmay alter several genes, which synergistically
modulate the same pathway, as in 17p13.1 copy loss decreasing
expression of p53 itself and the p53 modifiers, RPL26 and
KDM6B (JMJD3) (Figure 4). Second, several CNAs may modify
the same pathway. For example, 1q23.3 copy gain (MDM4 and
RFWD2), 9p21.3 copy loss (CDKN2A), 12q15 copy gain
(MDM2), 17p13.1 copy loss (TP53, RPL26, and KDM6B), and
19q13.42 copy gain (BCL2L12) all function to decrease p53
activity (Figure 4). Third, certain single CNAs may alter comple-
mentary pathways, such as 12q15 amplification (CDK2, CDK4,
and MDM2), enhancing cell cycle progression and reducing
p53 activity (Figure 4). Fourth, multiple CNAs may modify
complementary pathways such as p53 signaling, apoptosis,
and cell cycle regulation (Figure 4).CanCNAs of p53 Pathway and Cell Cycle Components
in Individual Primary DLBCLs
After comprehensively defining CNAs that perturb p53 signaling
and cell cycle pathways in DLBCLs, we assessed the patterns
and combinations of alterations that occur in individual tumors.
When the primary DLBCLs were clustered in the space of the
CNAs that alter p53 pathway and cell cycle components, 66%
(118/180) of tumors had multiple alterations (termed ‘‘complex’’)
whereas the remaining 34% of tumors lacked these lesions
(designated ‘‘clean’’; Figure 5A). Primary DLBCLs with single
copy loss of 17p13.1 (TP53/RPL26/KDM6B) often had CNAs
perturbing an additional p53 modifier – 9p21.3 (CDKN2A/
ARF), 19q13.42 (BCL2L12), 12q15 (MDM2), or 1q23.3 (MDM4/
RFWD2) (Figure 5A). Of interest, CNAs of the respective
p53 modifiers, CDKN2A (ARF, 9p21.3), MDM2 (12q15), and
MDM4/RFWD2 (1q23.3) occurred in largely separate groups of
tumors (Figure 5A). DLBCLs with CNAs of p53 pathway
members frequently exhibited concurrent alterations of addi-
tional cell cycle components such as CCND3 (6p21.32), CDK6
(7q22.1), CDK2/CDK4 (12q15), and/or RB1 (13q14.2) or RBL2
(16q12.2) (Figure 5A). Tumors with ‘‘complex’’ patterns of p53
pathway and cell cycle components also had more total CNAs
than DLBCLs with ‘‘clean’’ p53/cell cycle signatures (Figure 5A,
bottom panel, S all CNAs, ‘‘complex’’ versus ‘‘clean’’ p < .0001cer Cell 22, 359–372, September 11, 2012 ª2012 Elsevier Inc. 365
Figure 5. CNAs of p53 Pathway and Cell
Cycle Components in Individual Primary
DLBCLs
(A) Primary DLBCLs clustered in the space of
CNAs that alter p53 pathway and cell cycle
components. CNAs and perturbed genes on the
left (rows) and individual tumors on top (columns).
CN gains, red; CN losses, blue; color intensity
corresponds to themagnitude of the CNA. Tumors
with CNAs of multiple p53 pathway and cell cycle
components, ‘‘complex’’; DLBCLs without these
lesions, ‘‘clean’’. Total CNAs (S all CNAs) in
‘‘complex’’ versus ‘‘clean’’ DLBCLs under heat
map, p < .0001, Mann-Whitney U test. TP53
mutations in ‘‘complex’’ versus ‘‘clean’’ DLBCLs at
top, 22%versus 7%, p < 0.005, Fisher’s one-sided
exact test.
(B) GSEA of p53 targets in ‘‘clean’’ versus
‘‘complex’’ DLBCLs. The 19K genes in the genome
were sorted from highest (left, white) to lowest
(right, gray) relative expression in ‘‘clean’’ versus
the ‘‘complex’’ DLBCLs (horizontal axis). The
p53 targets (V.P53_02, described in Figure S2C)
were located within the sorted genome and
their positions (hits) were found to be signifi-
cantly skewed toward the left end of the sorted
list (positive enrichment score, 0.31), reflecting
their statistically significant overexpression in
‘‘clean’’ as compared to ‘‘complex’’ DLBCLs
(p = 0.01).
(C) GSEA of a RB deficiency gene set in ‘‘complex’’ versus ‘‘clean’’ DLBCLs. GSEA was performed as in (B) except that genes were sorted from highest to lowest
expression in ‘‘complex’’ versus ‘‘clean’’ DLBCLs (horizontal axis). The positions of RB-deficiency gene set members (hits) were significantly skewed toward the
left end of the sorted list reflecting their overexpression in ‘‘complex’’ DLBCLs (positive enrichment score 0.79, p < 0.001).
(D) Ki67 immunohistochemistry of ‘‘complex’’ and ‘‘clean’’ DLBCLs. Representative ‘‘clean’’ (upper micrographs) and ‘‘complex’’ DLBCLs (lower micrographs)
(left). Scale bar represents 50 mm. Percentage Ki67-positive tumor cells in ‘‘complex’’ and ‘‘clean’’ DLBCLs (p = 0.019, Mann-Whitney U test) visualized as Box-
Plot (median, line; 25% and 75% quartile, box; whiskers, minimum to maximum) (right).
See also Figure S2 and Table S5.
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CNAs Perturb p53 and Cell Cycle in DLBCLand Figure S2A) and more frequent TP53 mutations (Figure 5A
top panel, ‘‘complex’’ 22% versus ‘‘clean’’ 7%, p < 0.005; Fig-
ure S2; Table S5). The patterns of ‘‘complex’’ versus ‘‘clean’’
CNAs of p53 pathway and cell cycle components and the asso-
ciation between ‘‘complex’’ signature and total CNAs were
confirmed in an independent series of 79 primary DLBCLs
(Figure S2B).
To further characterize ‘‘complex’’ versus ‘‘clean’’ tumors, we
performed gene set enrichment analysis (GSEA) with publicly
available series of p53 target genes and a RB-deficiency gene
set, which included multiple E2F targets (Knudsen and Knudsen,
2008). The GSEA computational method identifies statistically
significant, concordant differences in the transcript abundance
of a previously defined set of genes (such as p53 targets) in
two biological states (ie, ‘‘clean’’ versus ‘‘complex’’ primary
DLBCLs) (Subramanian et al., 2005). The p53 target transcripts
were significantly less abundant in ‘‘complex’’ DLBCLs, directly
linking their genetic signature of p53 deficiency with decreased
p53 activity (Figures 5B and S2C). Furthermore, the RB-defi-
ciency gene set was significantly enriched in ‘‘complex’’ DLBCLs
suggesting that these tumors had increased E2F-mediated cell
cycle progression (Figure 5C). Consistent with these obser-
vations, DLBCLs with ‘‘complex’’ CNA patterns also had sig-
nificantly higher proliferation indices as determined by Ki67
immunostaining (Figure 5D).366 Cancer Cell 22, 359–372, September 11, 2012 ª2012 Elsevier InStructural Complexity as a Significant Predictor
of Outcome
We next assessed the prognostic significance of the
‘‘complex’’ CNA pattern in the subset of patients who were
treated with rituxan, cyclophosphamide, adriamycin, oncovin,
and prednisone (R-CHOP) and had long-term follow up
(Tables S6 and S7). Patients with ‘‘complex’’ CNA patterns
had a 5 year overall survival of only 62%, whereas those
with ‘‘clean’’ CNA signatures were all cured (Figure 6A;
p = .001). The association between CN complexity and
outcome was independent of transcriptional COO categories
(Figure S3).
We next assessed the relationship of CN complexity and the
clinical IPI risk model. Although the IPI was highly predictive of
outcome (low/low-intermediate versus high-intermediate/high;
Figure 6B, left panel), the CNA pattern significantly increased
prognostic accuracy (Figure 6B, middle and right panels). In
both the low/low-intermediate and high-intermediate/high-risk
groups, patients whose tumors had ‘‘complex’’ CNAs had signif-
icantly shorter overall survivals, whereas all patients with ‘‘clean’’
CNA patterns were cured (Figure 6B, middle and right panels).
The contribution of the CNA pattern to IPI outcome stratification
was also confirmed by a Cox-proportional hazard model (p <
.001; Supplemental Experimental Procedures). Taken together,
these data provide a structural basis for deregulated cell cycle,c.
Figure 6. Prognostic Significance of
‘‘Complex’’ versus ‘‘Clean’’ CNA Pattern in
DLBCLs
(A) Overall survival of R-CHOP treated DLBCL
patients with ‘‘complex’’ versus ‘‘clean’’ CNA
patterns (p = .001, log rank test).
(B) CNA patterns in IPI risk groups. Overall survival
of R-CHOP treated DLBCL patients in low/low-
intermediate and high-intermediate/high IPI risk
groups (left). Overall survival of low/low-interme-
diate and high-intermediate/high risk patients with
‘‘complex’’ versus ‘‘clean’’ CNA patterns (middle
and right).
See also Figure S3 and Tables S6 and S7.
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CNAs Perturb p53 and Cell Cycle in DLBCLincreased cellular proliferation, and unfavorable outcome in
DLBCL.
Targeting Deregulated Cell Cycle with Broad-Acting
CDK Inhibitors
The predictive value of the ‘‘complex’’ CNA pattern and its asso-
ciation with deregulated cell cycle and increased activation of
CDK4/6, CDK2, and likely CDK1 (Figure 4) prompted us to
assess the activity of a broad-acting CDK inhibitor, such as fla-
vopiridol (Lapenna and Giordano, 2009), in DLBCL. We used
a panel of DLBCL cell lines derived from patients with
relapsed/refractory disease; all lines have decreased or absent
p53 activity and CNAs of cell cycle components including
CDKN2A, CCND3, CDK4, CDK6, CDK2, and/or copy loss of
RB1 (Figure S4A). Flavopiridol, which inhibits CDK4/6, CDK2,
and CDK1 (and CDK9), decreased the cellular proliferation of
the DLBCL cell lines at nanomolar doses (Figure 7A). Similar
results were obtained with a second pan-CDK inhibitor, AT-
7519 (Figure S4B). Of interest, a DLBCL cell line with single
copyRB1 loss (DHL7), was less sensitive to lower doses of flavo-
piridol (Figure 7A) consistent with RB1 being downstream of the
targeted CDKs.
In these DLBCL cell lines, treatment with the pan-CDK inhibitor
decreased S phase and induced cell cycle arrest (Figure 7B). In
addition, the broad-acting CDK inhibitor increased apoptosis,
as assessed by subG1 peaks and Annexin V/7-AAD staining
(Figures 7B and 7C), and decreased the phosphorylation of
RB1 at CDK4/6 and CDK2-specific sites (pS780 and pT821,
respectively) (Figures 7D and S4B). In multiple DLBCL xenograft
models, flavopiridol treatment significantly reduced tumor
growth and lymphoma infiltration of bone marrow and spleen
(Figures 8A–8C and S5). Taken together, these data suggest
that genetically driven cell cycle deregulation in DLBCL may be
amenable to targeted therapy.
DISCUSSION
Using a combination of high-density (HD)-SNP arrays, gene
expression profiling, and pathway analyses, we have compre-
hensively defined CNAs, associated candidate driver genes,
and perturbed signaling pathways in a large series of newly diag-
nosed DLBCLs. The precision of the HD-SNP platform allowed
us to precisely determine the boundaries of recurrent CNAs
and distinguish alterations that were unique to DLBCL from
ones that were shared with nonhematologic malignancies. TheCanmultiple low frequency CNAs prompted us to systematically
evaluate the alterations and associated genes with pathway
analyses. The approach revealed a large complementary set of
CNAs that decreased p53 activity and perturbed cell cycle regu-
lation. The CNA-associated signature of p53 deficiency and cell
cycle deregulation was highly predictive for outcome and poten-
tially amenable to targeted therapy.
p53 Deficiency
The CNA-associated pattern of deregulated p53 signaling was
detected in 66% of newly diagnosed DLBCLs, of note because
somatic inactivating mutations of TP53 are much less common
in DLBCLs than in multiple epithelial malignancies. For example,
only 16% of tumors in the current series of primary DLBCLs
exhibited hemizygous TP53mutations, and the majority of these
were in ‘‘complex’’ tumors with additional CNAs of p53 path-
way members. All of the CNAs of p53 modulators and signal-
ing pathway components had the same functional effect—
decreased abundance of functional p53 and reduced levels of
p53 targets. In addition to identifying previously described
CNAs of p53 modifiers, such as CDKN2A (ARF) and MDM2
and TP53 itself, we found CNAs of the p53 regulators MDM4,
RFWD2, and BCL2L12 in DLBCL. We also defined a ‘‘deletion
block’’ on chromosome 17p13 that includes two additional p53
modifiers, KDM6B and RPL26, as well as TP53. The concurrent
loss of TP53, RPL26, and KDM6B may perturb p53 signaling
to a greater degree than anticipated in tumors with hemizygous
17p13 deletions. The gain of both MDM4 and RFWD2 at 1q23.3
delineates an additional ‘‘amplicon block’’ that serves to de-
crease p53 activity. These insights regarding genetic mecha-
nisms that reduce normal p53 activity in DLBCL may inform
targeted treatment strategies. For example, two recently devel-
oped p53 inhibitors are predicated on disrupting the interaction
between functional p53 and the p53 modifiers, MDM2 and
MDM4 (Bernal et al., 2010; Shangary and Wang, 2008).
Perturbed Cell Cycle Regulation
Besides copy loss of the cyclin D-dependent kinase inhibitor,
p16INK4A, we identified copy gain of CDK4, CDK6, and CCND3,
themost abundant and essential D-type cyclin in germinal center
B cells (Cato et al., 2011). In addition to the likely relief of p53/
p21-dependent CDK2 inhibition, we also found copy gain of
CDK2 in association with CDK4 (and MDM2) in a chromosome
12q15 ‘‘amplicon block’’ and copy loss of both RB1 and RBL2.
There was a highly significant CNA-associated signature ofcer Cell 22, 359–372, September 11, 2012 ª2012 Elsevier Inc. 367
Figure 7. Targeting Deregulated Cell Cycle with a Pan-CDK Inhibitor
DLBCL cell lines with decreased or absent p53 activity and CNAs of CDKN2A, CCND3, CDK4, CDK6, CDK2, and/or copy loss of RB1were treated with the pan-
CDK inhibitor, flavopiridol, which blocks CDK4/6, CDK2, and CDK1 (and CDK9).
(A) Proliferation following flavopiridol treatment (50–400 nM) for 1–4 days. DLBCL cell lines names at top.
(B) Cell cycle analysis following 72 hr flavopiridol treatment (400 nM) (DMSO control).
(C) Apoptosis (Annexin V staining) following 72 hr flavopiridol treatment (100–400 nM).
(D) RB1 phosphorylation at CDK4/6 and CDK2-specific sites (pS870 and pT821, respectively) following 24 hr flavopiridol treatment (100–400 nM). (Note that Rb is
itself an E2F target; Knudsen and Knudsen, 2008.)
Error bars show the SD of triplicates. See also Figure S4.
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CNAs Perturb p53 and Cell Cycle in DLBCLincreased E2F transcriptional activity underscoring the func-
tional consequences of these genetic alterations.
The p53 and cell cycle component CNAs occur together in
a comprehensive ‘‘complex’’ pattern in 66% of the primary
DLBCLs; the remaining tumors have only rare CNAs. Gene set
enrichment analysis revealed that DLBCLs with ‘‘complex’’
CNAs had significantly less abundant expression of p53 target
genes, directly linking their genetic signature of p53 deficiency
with decreased p53 activity. In addition, these ‘‘complex’’
tumors exhibited enrichment of E2F targets by GSEA and
increased cellular proliferation by Ki67 immunostaining. Most
importantly, the ‘‘complex’’ CNA pattern is highly predictive for
outcome in R-CHOP treated DLBCL patients. These findings,
which provide a mechanistic basis for previous observations
regarding the prognostic significance of cellular proliferation in
DLBCL (Broyde et al., 2009; Grogan et al., 1988; Salles et al.,
2011), should be further validated in future DLBCL series.368 Cancer Cell 22, 359–372, September 11, 2012 ª2012 Elsevier InThe current study highlights the value of a comprehensive
approach to identify CNA-defined alterations of p53 and cell
cycle regulatory pathways, some of which have been character-
ized on an individual or selective basis and associated with
outcome in earlier studies (Faber and Chiles, 2007; Jardin
et al., 2010; Sa´nchez-Beato et al., 2003; Winter et al., 2010;
Young et al., 2008). We find that a single CNA (17p13.1) targets
several p53 modulators, multiple CNAs perturb p53 activity
(1q23.3, 9p21.3, 12q15, 17p13.1, and 19q13.42) and a single
CNA (12q15/MDM2, CDK2, and CDK4) modulates both p53
signaling and cell cycle progression. Because many of these
CNAs are shared with additional nonhematologic malignancies
(Figure 2), these findings may also be applicable to other tumor
types. In fact, an array comparative genomic hybridization-
defined ‘‘complex’’ pattern of copy gains and losses was
recently associated with high mitotic counts and TP53 alter-
ations in breast cancer (reviewed in Kwei et al., 2010).c.
Figure 8. In Vivo Efficacy of a Pan-CDK Inhibitor in DLBCL Xenografts
(A) Bioluminescense of flavopiridol- or vehicle-treated NOD SCID Il2rgnull (NSG) mice xenotransplanted with luciferized mCherry+ (Toledo, Ly4, or Ly1) DLBCL
cells. Error bars show the SEM.
(B) Lymphoma infiltration in the bone marrow of NSG mice (in A) following flavopiridol or vehicle treatment. Single cell suspensions of bone marrow of tumor-
bearing mice were evaluated for mCherry+ DLBCL cells by flow cytometry and visualized as Box-Plot (median, line; 25% and 75% quartile, box; whiskers,
minimum to maximum). P values were obtained with a Mann-Whitney U test.
(C) Immunohistochemical analysis of lymphoma (Toledo) cell infiltration in spleens of vehicle- and flavopiridol-treatedmice: H&E; anti-humanCD20, and anti-Ki67
immunostaining. Scale bar represents 50 mm.
See also Figure S5.
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CNAs Perturb p53 and Cell Cycle in DLBCLGenomic Instability in the Subset of DLBCLs with
Perturbed p53 Signaling and Cell Cycle Deregulation
In our DLBCL series, tumors with ‘‘complex’’ CNAs of p53 and
cell cycle components also had significantly more of the addi-
tional recurrent CNAs, including focal and regional alterations
and gains or losses of half or whole chromosomes (Figure S2A).
The basis for the increased genomic instability in these ‘‘com-
plex’’ DLBCLs remains to be defined but may be linked to the
deficiencies in p53 signaling and perturbed cell cycle regulation.
Numerical and structural chromosome instability (CIN) is better
tolerated in a p53-deficient background and alterations of
TP53,MDM2,MDM4 (MDMX), the CDK2 partner, CCNE1 (cyclin
E1), and RB1 all foster CIN (Hernando et al., 2004; Matijasevic
et al., 2008; Shlien et al., 2008; Thompson et al., 2010; Wang
et al., 2008). In the setting of hyperactive CDKs and DNA
damage, cell cycle progression further increases genomic insta-
bility (Malumbres and Barbacid, 2009).
In addition to CNAs of the p53 apoptotic pathway, DLBCLs
with the ‘‘complex’’ pattern exhibit alterations of other apopto-
tic members including BCL2/18q21.33, FAS/10q23.32, and
TNFRF10B/8p21.3 (Figure S2A). CNAs of immune recogni-
tion molecules, including HLA-B, HLA-C, MICA, and MICB
(6q21.33), B2M (15q21.1), CD58/1p13.1, and TNFSF9 (19p13.3)
also largely occur in DLBCLs with ‘‘complex’’ patterns (Fig-
ure S2A). These data highlight the importance of evaluating
specific genetic alterations in the context of a more comprehen-
sive assessment of CNAs and associated genomic instability.CanClinical Significance
The prognostic value of the perturbed p53 signaling/cell cycle
deregulation signature prompted us to evaluate the activity of
pan-CDK inhibitors in DLBCL. Following treatment, DLBCL cell
lines with CNAs of p53 signaling and cell cycle components
(with or without additional p53 mutations) exhibited decreased
proliferation and RB1 phosphorylation and increased apoptosis
in vitro and significantly reduced tumor growth in vivo. Therefore,
prognostically significant, genetically driven cell cycle deregula-
tion in DLBCL may be amenable to targeted treatment.
EXPERIMENTAL PROCEDURES
Patients and Primary Tumor Samples
High molecular weight DNA and total RNA were extracted from frozen biopsy
specimens of newly diagnosed, previously untreated primary DLBCLs with
R80% tumor involvement according to Institutional Review Board (IRB)-
approved protocols from three institutions (Mayo Clinic, Brigham & Women
Hospital, and Dana-Farber Cancer Institute). For one subset of patients,
informed consent was obtained (Mayo Clinic). For other patients, a waiver to
obtain informed consent was granted by the local IRBs because otherwise dis-
carded tissue was used. The series included 72 DLBCLs from patients who
were treated with a rituxan-containing, anthracycline-based combination
chemotherapy regimen (R-CHOP-like) and had long-term follow up; 68of these
patients had available information on all clinical parameters in the IPI (Table S6).
HD-SNP Array Analysis and Expression Profiling
Primary DLBCL DNA samples and normal DNA specimens were profiled on
Affymetrix HD-SNP arrays 6.0 (Supplemental Experimental Procedures). Forcer Cell 22, 359–372, September 11, 2012 ª2012 Elsevier Inc. 369
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CNAs Perturb p53 and Cell Cycle in DLBCLthe detection of CN alterations, the SNP array 6.0 data was processed through
a previously described analytical pipeline (Nature, 2008). Across-sample
GISTIC analysis of the segmented data was carried out to identify statistically
significant CNAs (Supplemental Experimental Procedures) (Beroukhim et al.,
2007). Alteration regions with FDR q values below .25 were considered signif-
icant. Within each region, a peak (or peaks) was identified as the contiguous
set (or sets) of loci with highest q values. To visualize the distribution of alter-
ations across samples, we created a matrix with each entry indicating the
presence/absence of an alteration (row) in a given sample (column).
RNA samples from 169 of the primary DLBCLs were transcriptionally pro-
filed, and the data were processed using Affymetrix MAS5 summarization
method (Supplemental Experimental Procedures).
Integrative Analysis
Cis-Acting Alteration Signatures
The genes within the peak (region) of each GISTIC-identified alteration were
tested for an association between their expression (transcript abundance)
and the presence/absence of the harboring alteration by a two-group t statistic
with unequal variance. The cis-acting alteration signature for a given alteration
was then defined as the set of within-peak (-region) transcripts with FDR
q values% .25.
Trans-Acting Alteration Signatures
The transcripts from genes, which were outside an alteration peak, were also
evaluated for an association between their expression and the respective copy
number alteration. The top 6,000 transcripts ranked by across-sample median
absolute deviation (MAD) were used as the candidate list. The trans-acting
alteration signature for an alteration was defined as the set of outside-peak
transcripts with FDR q values% .25 and fold changeR 1.3.
Pathway and TF Binding Site Enrichment Analysis
The global cis-acting signature, defined as the union of all of the individual cis-
acting alteration signatures, was analyzed for pathway enrichment by testing
the signature against curated gene sets from the MSigDB repository (C2
collection, version 2.5) (Supplemental Experimental Procedures). FDR-cor-
rected q values were computed based on the hypergeometric distribution.
The global trans-acting signature was defined as the union of all trans-acting
alteration signatures. The union of the global cis-acting and trans-acting signa-
tures was then analyzed for enrichment of targets of specific TFs using the
curated sets of TF targets in the MSigDB C3 collection (Supplemental Exper-
imental Procedures). FDR-corrected q values were computed based on the
hypergeometric distribution.
Xenograft Models
All animal studies were performed according to Dana-Farber Cancer Institute
Institutional Animal Care and Use Committee-approved protocols.
ACCESSION NUMBERS
The Gene Expression Omnibus accession number for the HD-SNP 6.0 and
gene expression data reported in this paper is GSE34171.
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